Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter study of intravenous Zometa for pain and quality of life in patients with bone metastases from breast or prostate cancer
2004-005088-17Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in bone metastases, breast cancer and prostate cancer (PCa), sponsored by Novartis. Primary endpoint: Pain assessments. Started Apr 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
bone metastasesbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2004-005088-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005088-17.